Serum GH binding protein activities identifies the heterozygous carriers for Laron type dwarfism
- PMID: 2800930
- DOI: 10.1530/acta.0.1210603
Serum GH binding protein activities identifies the heterozygous carriers for Laron type dwarfism
Abstract
Measurement of GH-binding protein activity and IGF-I was carried out in the sera of 13 patients with Laron type dwarfism, a syndrome caused by a lack of GH receptors which leads to impairment of IGF-I generation, and those of 16 of their close relatives. GH binding protein activity was measured by incubating 125I-hGH with 100 microliters serum in the presence and in the absence of excess unlabelled hGH, followed by separation of specifically bound 125I-hGH binding protein complexes from free 125I-hGH by gel filtration. The results are expressed as percent specific binding relative to an adult reference serum. IGF-I was determined by RIA after acid extraction on octadecylsilane silica columns. All Laron type dwarfism patients had no, or only negligible GH binding protein activity, which supports the evidence that serum GH binding protein corresponds to the extracellular domain of the membranal GH receptor. Eight of the 16 relatives had serum GH binding protein activity more than 2 SD below the mean for age, a finding considered to denote heterozygocity for their molecular defect disease. The significant correlation (p less than 0.001) between serum GH binding protein activity and IGF-I levels supports this conclusion. The ability to define heterozygotes of Laron type dwarfism will be helpful in genetic counselling.
Similar articles
-
Absence of serum growth hormone binding protein in patients with growth hormone receptor deficiency (Laron dwarfism).Proc Natl Acad Sci U S A. 1987 Jul;84(13):4636-40. doi: 10.1073/pnas.84.13.4636. Proc Natl Acad Sci U S A. 1987. PMID: 3474620 Free PMC article.
-
Laron-type dwarfism with apparently normal high affinity serum growth hormone-binding protein.Clin Endocrinol (Oxf). 1991 Aug;35(2):179-85. doi: 10.1111/j.1365-2265.1991.tb03518.x. Clin Endocrinol (Oxf). 1991. PMID: 1934534
-
IGF binding protein 3 in patients with Laron type dwarfism: effect of exogenous rIGF-I.Clin Endocrinol (Oxf). 1992 Mar;36(3):301-4. doi: 10.1111/j.1365-2265.1992.tb01449.x. Clin Endocrinol (Oxf). 1992. PMID: 1373347
-
Laron syndrome - A historical perspective.Rev Endocr Metab Disord. 2021 Mar;22(1):31-41. doi: 10.1007/s11154-020-09595-0. Epub 2020 Sep 22. Rev Endocr Metab Disord. 2021. PMID: 32964395 Review.
-
Pseudohypopituitary syndromes.Baillieres Clin Endocrinol Metab. 1992 Jul;6(3):557-71. doi: 10.1016/s0950-351x(05)80112-0. Baillieres Clin Endocrinol Metab. 1992. PMID: 1524552 Review.
Cited by
-
Height-reducing variants and selection for short stature in Sardinia.Nat Genet. 2015 Nov;47(11):1352-1356. doi: 10.1038/ng.3403. Epub 2015 Sep 14. Nat Genet. 2015. PMID: 26366551 Free PMC article.
-
Nonclassical GH Insensitivity: Characterization of Mild Abnormalities of GH Action.Endocr Rev. 2019 Apr 1;40(2):476-505. doi: 10.1210/er.2018-00146. Endocr Rev. 2019. PMID: 30265312 Free PMC article. Review.
-
An update on Laron syndrome.Arch Dis Child. 1993 Mar;68(3):345-6. doi: 10.1136/adc.68.3.345. Arch Dis Child. 1993. PMID: 8466235 Free PMC article. No abstract available.
-
Screening tests for growth hormone deficiency.J R Soc Med. 1995 Mar;88(3):161P-165P. J R Soc Med. 1995. PMID: 7538588 Free PMC article. Review. No abstract available.
-
The relevance of pharmacokinetics in the development of biotechnology products.Eur J Drug Metab Pharmacokinet. 1996 Apr-Jun;21(2):93-103. doi: 10.1007/BF03190257. Eur J Drug Metab Pharmacokinet. 1996. PMID: 8839682 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical